GlassScriptPhysician profile
Yana Turkowski
NPI 1841842937
$5,932.40
in general payments reported to CMS, 2019-2025
27 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $62.02 · 2021: $376 · 2022: $431 · 2023: $931 · 2024: $1,383 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,898.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,259.40 | 2023-2025 | Rinvoq |
| Ucb, INC. | $578.72 | 2025 | Bimzelx |
| Janssen Pharmaceuticals, INC | $485.68 | 2021-2023 | Xarelto |
| Arcutis Biotherapeutics, INC. | $466.60 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $424.87 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $284.86 | 2024-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $276.87 | 2023-2025 | Nemluvio, Twyneo, Epsolay |
| E.R. Squibb & Sons, L.L.C. | $255.15 | 2024 | Sotyktu |
| Genzyme Corporation | $212.91 | 2022-2025 | |
| Tempus Ai, INC | $158.76 | 2024 | |
| Pfizer INC. | $145.59 | 2019-2020 | |
| Amgen INC. | $139.50 | 2025 | Otezla |
| Gilead Sciences, INC. | $131.80 | 2021-2023 | Trodelvy |
| Krystal Biotech INC | $125.00 | 2023 | Vyjuvek |
| Corcept Therapeutics | $109.92 | 2023 | Korlym |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $102.07 | 2025 | |
| Novo Nordisk INC | $99.86 | 2023 | |
| Glaxosmithkline, LLC. | $98.22 | 2022 | |
| Sun Pharmaceutical Industries INC. | $96.25 | 2025 | |
| Insmed, INC. | $89.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $77.22 | 2025 | |
| Incyte Corporation | $66.53 | 2024 | Opzelura |
| Astrazeneca Pharmaceuticals LP | $62.52 | 2019-2021 | |
| Organon LLC | $57.54 | 2025 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $21.81 | 2022 | |
| Viiv Healthcare Company | $21.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yana Turkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.